Navigation Links
Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
Date:2/7/2008

PT. RICHMOND, Calif., Feb. 7 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. today announced that Glenn A. Oclassen, Chief Executive Officer & President, will present at the 10th Annual BIO CEO & Investor Conference at the Waldorf-Astoria Hotel in New York City on Tuesday, February 12, 2008 at 10:15 AM Eastern Time.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs. Transcept development projects leverage new understanding of CNS conditions to provide additional uses and enhanced clinical benefits for existing active agents. The lead Transcept product, Intermezzo(R) (zolpidem tartrate lozenge), is a low dose sublingual formulation of zolpidem for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep. Phase 3 clinical trials have been completed for Intermezzo(R) and Transcept plans to submit an NDA in the third quarter of 2008. Another product being developed by Transcept is TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for the treatment of dopamine associated psychiatric disorders. TO-2060 has recently completed a successful dose ranging trial for the treatment of alcohol use disorder and a full clinical development program has begun. For further information, please visit the company's website at: http://www.transcept.com.

Contacts:

Transcept Pharmaceuticals, Inc.

Michael Gill

Director of Communications

(510) 215-3575

mgill@transcept.com

The Ruth Group

Investors / Media

Stephanie Carrington / Jason Rando

(646) 536-7017 / 7025

scarrington@theruthgroup.com

jrando@theruthgroup.com


'/>"/>
SOURCE Transcept Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
2. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
3. Transcept Pharmaceuticals to Present at 19th Annual Piper Jaffray Health Care Conference
4. Transcept Pharmaceuticals to Present at RBC Capital Markets 2007 Healthcare Conference
5. Transcept Pharmaceuticals to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... ... July 17, 2017 , ... ... and Its Treatments during Pregnancy , studies take a closer look at maternal ... a developing baby with one study showing newer medications may be safer choices. ...
(Date:7/17/2017)... Connecticut (PRWEB) , ... July 17, 2017 , ... McGraw ... Enhance Patient Care and Train Next Generation of Healthcare Clinicians , NORWALK, Connecticut ... McGraw-Hill, is continuing its legacy of investing in community health by pledging up to ...
(Date:7/17/2017)... ... July 17, 2017 , ... Altec Products, Inc., a ... Advanced Admin Training in Atlanta, Georgia. The four-day training session, which begins ... them to manage DocLink more efficiently and effectively. , Covering topics such as ...
(Date:7/17/2017)... ... July 17, 2017 , ... ... For” by the Chronicle of Higher Education for the sixth consecutive year, and ... has campuses in Pomona, California and Lebanon, Oregon, was recognized in seven categories: ...
(Date:7/17/2017)... ... July 17, 2017 , ... Dr. Teotia is honored to receive the ... in plastic and reconstructive surgery. RealSelf is the top online resource for patients who ... last year alone. Dr. Teotia has also been asked to be a Feature Medical ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... -- Bayer has awarded grants totaling more than $2 million to ... Bayer Hemophilia Awards Program (BHAP). Four U.S. clinicians and researchers ... and Uniformed Services University of the Health Sciences in ... were announced last night during a reception at the International ... Berlin, Germany . ...
(Date:7/11/2017)... JERUSALEM , July 11, 2017 Oramed ... ), a clinical-stage pharmaceutical company focused on the development ... U.S. Food and Drug Administration (FDA) has agreed to ... successfully completed Phase IIb trial of its oral insulin ... The Phase IIb trial met primary and secondary endpoints ...
(Date:7/10/2017)... CARLSBAD, Calif. , July 10, 2017  The ... in Boston, MA at the ... unequaled value and unparalleled access to global decision makers ... to draw 800+ life science leaders during two impactful ... Boston, and provides delegates with additional networking opportunities with ...
Breaking Medicine Technology: